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Abstract 
Aims: Atrial anti-arrhythmic effects of β-adrenoceptor antagonists (β-blockers) may involve both a 
suppression of pro-arrhythmic effects of catecholamines, and an adaptational electrophysiological 
response to chronic β-blocker use; so-called “pharmacological remodelling”. In human atrium, such 
remodelling decreases the transient outward (Ito) and inward rectifier (IK1) K+ currents, and increases 
the cellular action potential duration (APD) and effective refractory period (ERP). However, the 
consequences of these changes on mechanisms of genesis and maintenance of atrial fibrillation (AF) 
are unknown. Using mathematical modelling, we tested the hypothesis that the long-term adaptational 
decrease in human atrial Ito and IK1 caused by chronic β-blocker therapy, i.e., independent of acute 
electrophysiological effects of β-blockers, in an otherwise un-remodelled atrium, could suppress AF. 
Methods and results: Contemporary, biophysically detailed human atrial cell and tissue models, were 
used to investigate effects of the β-blocker based pharmacological remodelling. Chronic β-blockade-
remodelling prolonged atrial cell APD and ERP. The incidence of small amplitude APD alternans in 
the CRN model was reduced. At the 1D tissue level, β-blocker-remodelling decreased the maximum 
pacing rate at which APs could be conducted. At the 3D organ level, β-blocker-remodelling reduced 
the life span of re-entry scroll waves.  
Conclusion: This study improves our understanding of the electrophysiological mechanisms of AF 
suppression by chronic β-blocker therapy.  AF suppression may involve a reduced propensity for 
maintenance of re-entrant excitation waves, as a consequence of increased APD and ERP. 
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Condensed abstract: The atrial anti-arrhythmic effects of K+ current suppression due to chronic β-
blocker-therapy were computationally evaluated using contemporary mathematical descriptions of cell 
electrophysiology, and tissue models. The observed increase in cellular action potential duration and 
effective refractory periods may be the mechanism which attenuates re-entry life span, contributing to 
suppression of atrial fibrillation. 
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What’s New? 
• β-blockers have anti-arrhythmic effects involving suppression of catecholamine-induced after-
depolarisations. However, a less well understood effect of β-blockers is the adaptational 
electrophysiological remodelling (AER) resulting from long term β-blocker treatment of 
patients.  
• In human atrium, AER, by prolonging refractory period could, in theory, suppress atrial re-
entry, but effects of AER on re-entry have not been investigated previously. 
• This study implemented multi-scale models of human atria to investigate the functional 
impacts of β-blocker-induced AER on atrial electrical activity. 
• At the cellular level, AER prolonged atrial action potential duration and effective refractory 
period. 
• At the tissue level, AER reduced the propensity to re-entry genesis, decreased the maximum 
excitation rates of atrial activity, increased the meandering region of re-entry, and reduced re-
entry life-span.  
• This study provides mechanistic insights into the anti-arrhythmic effects of β-blockers.  
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1. Introduction 
Atrial fibrillation (AF) is  a common cardiac arrhythmia, affecting 1-2% of the general population 1. 
Currently available anti-arrhythmic drugs are moderately effective and safe, and an improved 
understanding of their action on atrial electrophysiology is warranted 2, 3. β-adrenoceptor antagonists 
(β-blockers) are used in AF treatment, mainly to control the ventricular rate by slowing atrio-
ventricular conduction 2, 4. Some clinical studies showed that β-blockers can prevent AF, convert it to 
sinus rhythm, or maintain sinus rhythm after it is restored 5, 6, and these drugs are most effective when 
adrenergic tone is high 6. AF from adrenergic stimulation is caused, in large part, by the effect of 
catecholamines to elevate intracellular Ca2+ that promotes arrhythmogenic action potential (AP) after-
depolarisations. β-stimulation is known to increase human atrial ICaL and IKur, and to elevate 
intracellular Ca2+ by a combined increase in ICaL and sarcoplasmic reticular Ca2+ content 6. The main 
mechanism of the anti-arrhythmic effects of β-blockers is generally accepted to involve suppression of 
such intracellular Ca2+-dependent after-depolarisations. However, an additional, less well understood 
and potentially anti-arrhythmic mechanism of β-blockers is an adaptational electrophysiological 
response to long-term β-blocker use; so called “pharmacological remodelling” 6, 7. Such 
pharmacological remodelling features an increase in the atrial AP duration (APD) and effective 
refractory period (ERP), as shown in rabbits 8, and subsequently in atrial myocytes isolated from 
patients in sinus rhythm 7, 9, 10; with ERP-prolongation correlating with β-blocker dose 11. This ERP-
prolongation could, in theory, contribute an atrial anti-arrhythmic, or a sinus rhythm-maintaining, 
effect, by lengthening the minimum wavelength required for re-entry, because re-entry wavelength = 
ERP x conduction velocity. The main ion current mechanisms underlying the increased APD and ERP 
in human atrium probably include a decrease in the density of the transient outward (Ito) and/or inward 
rectifier (IK1) K+ currents 7, 12, 13; with L-type Ca2+ (ICaL) and ultra-rapid delayed rectifier K+ (IKur) 
currents unaffected by chronic β-blockade 7, 9, 10, 12, 14, 15. However, the consequences of these ion 
current changes for the maintenance of re-entry are unknown. 
This question is difficult to address experimentally because of a lack of specific Ito and/or IK1 blockers. 
For example, the best available Ito blocker, 4-AP, inhibits IKur at ≥ 40-fold lower concentration than Ito 
16, and IKur is large in human atrium 16. Whereas these currents are distinguishable under voltage-clamp 
by their voltage dependence and kinetics, the pharmacological investigation of effects of their 
independent block on AP morphology and re-entry is hampered by such lack of specificity. However, 
this question is highly amenable to mathematical and computational investigation. Mathematical 
modelling has already proven useful in helping to clarify likely mechanisms of changes in human 
atrial APs 17, 18 and spiral 19 20 and scroll wave 20, 21 re-entry due to ion current or structural changes 
resulting from chronic AF. However, such models have not yet been used to investigate 
electrophysiological mechanisms of changes in APs and re-entry characteristics resulting from chronic 
β-blocker therapy. Our aim, therefore, was to use mathematical modelling to test the hypothesis that 
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the long-term adaptational decrease in human atrial Ito and IK1 caused by chronic β-blocker therapy, 
i.e., independent of acute electrophysiological effects of β-blockers, in an otherwise un-remodelled 
atrium, could suppress AF by inhibiting re-entry by increasing ERP. The Methods are detailed in the 
online Supplementary Materials. 
 
2. Results  
Three biophysically detailed models of human atrial cell APs, by Courtemanche et al. 22 (CRN), 
Grandi et al. 18 (Grandi), and Koivumaki et al. 23 (KT) were used. Abbreviations: gK1: conductance of 
IK1; gto: conductance of Ito; RP: resting potential; AP: action potential; dV/dtmax: maximum upstroke 
velocity of AP; OS: overshoot of AP; APD: AP duration; ΔAPD: change of APD; APDr: APD 
restitution; DI: diastolic interval; ERP: effective refractory period; PCL: pacing cycle length; CV: 
conduction velocity; CVr: CV restitution; VW: vulnerability window; LS: life span of re-entry. All 
numerical results from cell to 3D simulations are summarised in Table 1. 
2.1 Effects of β-blocker remodelling on single atrial cell APs 
The effects of chronic β-blocker remodelling on atrial cell APs and major ion currents are shown in 
Figure 1. β-blocker induced ion channel remodelling prolonged APD90 in the cell models (CRN by 
18%; Grandi by 30%; and KT by 27%). Such a prolongation of APD90 is in agreement with our 
experimental data from human atrial cells, in which chronic β-blockade increased APD90 by 19-28% 7, 
10, 14. Whereas APD30 was prolonged in Grandi (15%) and KT (15%) due to β-blockade, it was reduced 
in CRN (6%). The resting potential was shifted positively by 2 to 5 mV in the cell models, consistent 
with the effect of β-blockade to decrease IK1. The amplitudes of Ito and IK1 were reduced, while those 
of ICaL were largely unaffected, during the AP (Figure 1). AP clamp simulations (Supplementary 
Figure S2) showed similar results to those obtained from the cell model simulations, with a reduced 
IK1 and Ito whereas ICaL was reduced during the AP under β-blockade in the Grandi and KT models. 
There was a marginal increase of ICaL in the CRN model’s ICaL under β-blockade conditions. AP 
triangulation (Table 1) showed that the CRN model has a type 1 AP morphology, while the Grandi 
model’s high AP triangulation reflects a type 3 AP morphology. Triangulation was found to be 
increased under β-blocker remodelled conditions as compared to control by 43% (CRN), 41% 
(Grandi), and 30% (KT). β-blockade increased AP triangulation significantly indicating the 
prolonging effects on atrial repolarisation. The results of gK1 and gto parameter sensitivity analyses are 
shown in Supplementary Figure S3. Reduction of gK1 caused substantial prolongation of APD90 in all 
the models. APD30 was either prolonged (CRN), or remained largely unaffected (Grandi and KT 
models), due to a reduction of gK1. Contrary to experimental findings 18, a reduction of gto caused 
APD90 and APD30 to be reduced in the CRN model. The Grandi and KT models showed a 
prolongation of APD due to reduced gto. When gto was increased, APD (APD30 as well as APD90) 
reduced in all three models. 
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2.2 Effects of β-blocker remodelling on atrial cell APDr and ERP 
S1-S2 APDr (Figure 2) shows that β-blocker remodelling increased APD90 at slow pacing rates (i.e. 
large diastolic interval, DI) in all cell models. APD30 was abbreviated in the CRN model, while it was 
prolonged in the Grandi and KT models, due to β-blocker remodelling. β-blocker remodelling reduced 
the APDr maximum slopes in the CRN and Grandi models. In the KT model, β-blocker remodelling 
increased the APDr maximum slope. Thus, the action of β-blocker remodelling was to reduce the 
maximum slope of APD90 APDr, at least in the CRN and Grandi models. Irrespective of maximum 
APDr slopes, all models showed that β-blocker remodelling prevented atrial excitation electrical 
activity at fast pacing rates (i.e. small diastolic interval, DI), which are close to the rate of atrial 
excitations seen in AF. ERP (Figure 2) of single atrial cells was substantially increased by β-blocker 
remodelling. For slow pacing rates (PCL = 1 s), the ERP increased by 24% (CRN), 31% (Grandi), and 
18% (KT) due to β-blocker remodelling. Whereas the CRN and KT models were found to sustain 
faster pacing rates (approx. PCL ~ 290 ms) under both conditions, the Grandi model AP sustained a 
minimum PCL of 500 ms under control and 760 ms under remodelled conditions. Dynamic APDr 
showed the CRN model to sustain small amplitude APD alternans (of both APD90 and APD30) for 
PCLs at values between 295 and 410 ms (Figure 3). The KT model showed larger amplitude APD30 
alternans at PCL values between 200 and 263 ms. APD90 in this PCL range (200-263 ms, KT model) 
could not be computed as the AP did not achieve 90% repolarisation. In the CRN model, β-blockade 
significantly reduced the amplitude of APD alternans, as illustrated in Figure 3 and Supplementary 
Figure S5. At a PCL of 350 ms, the measured APD alternans amplitudes was 6.2 ms at 90% 
repolarisation (ΔAPD90) and 3.7 ms at 30% repolarisation (ΔAPD30) under control conditions, both of 
which were reduced to less than 0.15 ms under the β-blockade condition. In the KT model, β-blockade 
had negligible effect on APD alternans (Figure 3 and Figure S5). However, as Figure 3 shows, β-
blockade prevented atrial excitation of APs at faster pacing rates (PCL < 320 ms for CRN, and PCL < 
247 ms [at APD30] for KT). Alternans were not observed in the Grandi model. 
2.3 Effects of abrupt change of pacing rates in cell models 
The APD90 adaptation dynamics under control and β-blocker conditions are shown in Figure 4. The 
results of fitting a mono-exponential curve are given in Table S1. Under abrupt change of pacing from 
1 Hz to 1.67 Hz, β-blockade reduced the APD90 slow adaptation time constant by 15% (CRN and 
Grandi). Thus, the effect of β-blocker remodelling was to increase the atrial cell’s ability to adapt 
rapidly to an abrupt increase in pacing rate. The β-blocker remodelling did not have any significant 
effect on the APD90 adaptation time constant in the KT model. 
2.4 1D rate dependent conduction properties, vulnerability window, tissue ERP 
CV restitution data (Figure 4) showed that at slow pacing rates (DI ~ 1 s), successive propagations in 
the CRN and KT models had a CV similar to solitary wave CV. However, in the Grandi model, the 
CV of propagations due to S2 stimuli had a significant and inverse dependence on the pacing rate. β-
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blocker remodelling prevented the conduction of atrial excitation waves at high pacing rates. The 
computed maximum pacing rate for sustained excitation propagation was reduced in all three models; 
by 9.6% (CRN), 26.6% (Grandi), and 13.7% (KT) in the β-blocker remodelling condition. 
The wavelength of excitation propagation was calculated from 1D simulations (Table 1). At slow 
pacing rates, the β-blocker remodelling increased the excitation propagation wavelength. However, at 
fast pacing rates, β-blocker remodelling did not affect the wavelength (Table 1). The alterations of 
wavelength in the Grandi model due to β-blockade were small, reflecting the models rate adaptation 
capability.  
Unidirectional conduction block of a premature extrasystole can lead to initiation of AF by formation 
of re-entry 24-26. The time window within which unidirectional conduction block occurs in response to 
a premature stimulus applied to the refractory tail of a previous excitation wave is termed the temporal 
vulnerability window (VW). Temporal VW (Supplementary Figure S4, and Table 1) was increased in 
CRN and Grandi models, while it was reduced in the KT model, due to β-blockade. The temporal VW 
simulations also allowed estimation of tissue ERP. Tissue ERP was defined as the shortest coupling 
interval of a premature stimulus (during VW simulations) that elicited propagation in the 1D atrial 
strands. The action of β-blockade was to increase tissue ERP in all models (CRN by 8%; Grandi by 
19.6%; and KT by 10%). 
2.5 Scroll wave propagation in 3D organ model 
Further simulations were performed to investigate the effects of β-blocker remodelling on atrial 
tissue’s re-entrant excitation waves. The 3D atrial organ simulations are illustrated in Figure 5. Under 
control conditions, the re-entrant waves became trapped to a model boundary and thus became 
persistent (CRN), or continued as meandering mother rotors (Grandi and KT) throughout the whole 
period of simulation (5 s). Under β-blocker conditions, the re-entrant waves self-terminated at 0.35 s 
and 0.5 s, respectively, in the CRN and Grandi models, due to the wave front reaching the opening of 
the superior vena cava as illustrated in Figure 5. 
In the KT model, re-entrant excitation wave in the β-blocker remodelling condition was persistent for 
the duration (5 s) of the simulation.  However, the re-entrant waves meandered over larger areas as 
compared to the control condition. In addition, the excitation rate of localised atrial action potentials 
was also decreased by β-blocker remodelling. 
The total simulation time for 5 s of electrical activity was about 4 hours in each case of the 
simulations. 
 
3. Conclusions and Discussion 
3.1 Key findings 
The key finding was that computer simulation of human atrial Ito and IK1-remodelling by chronic β-
blocker therapy, independent of acute electrophysiological effects of β-blockers, revealed 
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electrophysiological mechanisms that may contribute to the atrial anti-arrhythmic actions of these 
drugs. Thus, we showed, in mathematical models of single atrial cells and 3-D tissues, that the 
reduction in Ito and IK1 could reduce the propensity for initiation and maintenance of re-entrant 
excitation waves, as a consequence of an increased APD, ERP and atrial excitation wavelength, as 
well as a suppression of atrial alternans. 
Reducing the repolarising currents IK1 and Ito prolonged the APD90 in all three cell models. This added 
weight to the idea that the APD increase observed experimentally is caused by the decrease in these 
two currents. The effects of β-blocker remodelling were also to increase cell and tissue ERP, 
consistent with experimental data from human atrial cells 7, 9, 10. The maximum slope of APDr has 
been proposed as a possible index to quantify tissue’s propensity to arrhythmic events 27, and that was 
reduced by the β-blocker remodelling. A reduced occurrence of alternans at cellular level may 
contribute to reducing the human atrial tissue’s propensity to dynamic heterogeneity 28. In simulations, 
the β-blocker-induced K+ current remodelling reduced the amplitude of APD alternans in the CRN 
model, though did not affect alternans behaviour in the KT model. In our simulations, the effect of 
blocking K+ currents on AP alternans was small. This may be due to the primary mechanisms of 
alternans being in the coupling between intracellular Ca2+ and AP dynamics 29 30, and that blocking Ito 
and IK1 does not significantly affect this coupling. Consideration of the effects of acute β-blockade on 
ICaL and SERCA concurrent with K+ current remodelling will more fully quantify the effects of β-
blockers on atrial APs and alternans behaviour and warrants future studies. The K+ current 
remodelling did, however, reduce the cell models’ abilities to sustain high rates of AP excitations (i.e. 
at PCL <320 ms in CRN and <247 ms in KT) and might be expected, therefore, to inhibit AP 
excitation at the fast rates normally encountered during AF 31. The observed stimulation failure at high 
rates due to β-blockade suggests a cellular mechanism which may contribute to the anti-arrhythmic 
effects of β-blockers. The adaptation of atrial APs to abrupt changes of pacing rate was seen to be 
more pronounced under β-blockade conditions as compared to control. This suggests an anti-
arrhythmic effects of β-block remodelling, as a previous study showed that a slower rate of APD 
adaptation can lead to EAD formation in a ventricular cell model 32. Dependence of AP excitation on 
pacing rate has been argued to give rise to dynamical conduction block at the tissue level independent 
of spatial heterogeneity 33. Therefore, an increased rapid adaptation to an altered pacing rate by β-
blockade may reduce the propensity to AF initiation. Such cell level AP adaptation correlates with 
tissue level heart rate (HR) adaptation, which when protracted has been suggested to be a pro-
arrhythmic risk factor 34. The CVr simulations showed that β-blocker remodelled tissue had a reduced 
propensity to sustain electrical propagations at faster pacing rates. CVr also showed that the Grandi 
model has a large CV adaptation. In the Grandi model, the excitations elicited by the S2 stimulus has 
appreciably smaller CV, possibly due to the strong influence of the slow intracellular Ca2+ dynamics 
on electrical properties in the Grandi model. The CV adaptation of the Grandi model may be due to 
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the strong coupling between the (faster) membrane ionic currents and the (slower) intracellular ionic 
dynamics. Thus at fast pacing rates, sufficient depolarising currents (e.g. INa) required for the 
propagation of a wave may not be available. 
The prolonged ERP due to β-blocker remodelling led to termination of 3D spiral waves (CRN and 
Grandi) and a reduced rate of localised excitation in all models. Our results agree with the K+ current 
block-mediated increase of spiral wave meander reported by Comtois et al. 35. The triangular but long 
ERP APs typical of atrial cells may also provide other mechanisms to prevent initiation of such spiral 
waves.  
Grandi et al. 18 and Workman et al. 11 helped show that the major ionic currents implicated in the 
maintenance of AF include some of those central to the present study. Indeed, the involvement of IK1 
and Ito changes in arrythmogenesis have also been explored in previous mathematical modelling 
studies for atria and ventricles 17, 19, 36, 37. Zhang et al. 17 used two human atrial cell models to 
demonstrate that an increase of IK1 reduces cell APD dramatically. This work was subsequently 
extended, in a multi-scale study 21, which showed that such IK1 increase was pro-arrhythmic. The other 
repolarising current central to this study, Ito, has  been implicated in explaining the type 1 APs in 
human atrial cells 22. Although APD in the CRN model is abbreviated by Ito suppression 
(Supplementary Figure S3), Pandit et al. 19 have shown that suppression of Ito leads to re-entrant wave 
disorganisation and termination. That observation may be due in part to the small APD abbreviation in 
their model (by 10% due to a 50% block of Ito) which still allows the CRN type re-entrant wave self-
termination. The responses to Ito reduction in the Grandi and KT models are consistent with a recent 
dynamic-clamp study 13, in which a progressive selective Ito decrease prolonged early and late 
repolarisation in human atrial cells (Supplementary Figure S3), and may better suit the demonstration 
of re-entrant wave self-termination due to Ito suppression. 
3.2 Limitations of the study 
1) Some limitations of the CRN, Grandi and KT models have been discussed elsewhere 18, 22, 23. Of 
note, our simulations show that the KT AP is more triangular and shorter than our experimental 
observations 7, 12. 2) In our multi-cellular models, electrical and spatial homogeneity was assumed, 
whereas human atria are electrically and spatially heterogeneous 38. 3) Inter-cellular coupling was 
modelled to give a CV of 0.3 mm/ms, whereas the CV in atria has been estimated over a wide range of 
values 39. 4) Whilst studies in human atrial cells showed that chronic β-blocker therapy in patients 
significantly remodelled Ito and IK1, and not ICaL or IKur 7, 9, 10, 12-15, no quantitative data are available on 
other currents (e.g. IKACh, INa/Ca, IKr, IKCa), or [Ca2+]i, and so their potential remodelling by chronic β-
blocker therapy should not be excluded. Adrenergic stimulation or β-blockade may also affect gap 
junction function or expression 40 41 and thereby alter intercellular propagation. 5) This study sought to 
simulate only the long-term adaptational changes in ion currents by chronic β-blocker therapy, i.e., 
independent of acute electrophysiological effects of β-blockers, and future studies may attempt to 
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model the combination of the chronic and acute effects. 6) The effect of β-blockade to slow the sino-
atrial node and thus heart rate was not incorporated in the model, and although atrial cellular ERP 
prolongation by chronic β-blockade occurs after adjusting for heart rate 7, future modelling studies 
could compare effects of chronic β-blockade on re-entry characteristics at different sinus rates. 7) The 
ion current data used to inform the present mathematical models were obtained from studies of 
patients who were taking β1-selective blockers, thus excluding those taking other β-blockers such as 
propranolol (β1/β2-blocker), sotalol (β1/β2/IKr blocker) or carvedilol (β1/β2/α1-blocker). The effects of 
chronic non-β1-selective therapy on human atrial cellular electrophysiology are unknown. However, in 
line with the present data, 24 days treatment of rabbits with propranolol prolonged atrial tissue APD90 
8, and 8 weeks carvedilol prolonged atrial cell APD90 42. 8) Whereas human atrial cellular ERP 
prolongation has been correlated with β1-blocker dose 11, only limited data are available on Ito or IK1 at 
different doses, so dose-dependency of the β-blocker effect on ion currents was not modelled here. 9) 
Since atrial APD and ERP may be shortened in “vagal” forms of AF, as well as by remodelling from 
chronic AF or LVSD 3, APD-prolongation from chronic β-blocker therapy might be predicted to 
attenuate or oppose such shortening. However, experimental data from human atrial cells under such 
conditions are lacking, and effects of chronic β-blocker therapy under conditions of increased vagal 
tone or myocardial disease were not modelled in the present study. 10) We acknowledge that in 
clinical practice and in the guidelines, class 1C and class 3 drugs are the preferred choice for 
interrupting AF or for the maintenance of sinus rhythm. Nevertheless, an improved understanding of 
the mechanisms of action of anti-arrhythmic drugs from any class, as gained in the present theoretical 
study on class II drugs, may aid the search for improved drug treatments for the prevention of AF.  
3.3 Conclusion and clinical significance  
In patients, suppression of AF by treatment with β-blockers likely involves the combined action of 1) 
acute attenuation of pro-arrhythmic effects of adrenergic-stimulation (after-depolarisations resulting 
from increased ICaL and [Ca2+]i) and 2) an ERP-prolonging adaptation to the long-term treatment; so-
called pharmacological remodelling 6. The present study improves our understanding of the 
electrophysiological mechanisms and consequences of the pharmacological remodelling-induced ERP 
increase. Thus we show, with mathematical modelling of single cells and 3-D tissues, that the anti-
arrhythmic effect of chronic β-blockade in human atria probably involves a reduced propensity for 
initiation and maintenance of spiral wave re-entry, as a consequence of an increased APD and ERP 
and a suppression of alternans, due to reduced IK1 and Ito.  
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Figure legends 
 
FIGURE 1 Simulated AP and ion current profiles under control and β-block induced remodelling 
conditions using the CRN (column A), Grandi (column B) and KT (column C) models. Top row 
shows AP, middle row IK1, third row shows Ito, and bottom row shows ICaL profiles.  
 
FIGURE 2 Cellular S1-S2 APDr and ERP restitution curves computed from the CRN (Column A), 
Grandi (Column B), and KT (Column C) cell models. Top panels show APD90 restitution curves, 
middle panels show APD30 restitution curves, while bottom panels show ERP restitution curves. 
 
FIGURE 3 Alternans manifested by bifurcation of dynamic APD restitution curves in CRN (left hand 
panels) and KT (right hand panels) cell models. APD90 and APD30 panels show absolute values of 
APD at 90% and 30% repolarisation and their maximal and minimal values when alternans occurs. 
ΔAPD90 and ΔAPD30 panels show the absolute differences between the maximal and minimal APDs 
(i.e., alternans amplitudes) under control and β-blockade conditions.  
 
FIGURE 4 Effects of abrupt change of PCL on APD90 and CVr in CRN (column A), Grandi (column 
B) and KT (column C) models. Top panels: The cell models were paced under control and β-block 
induced remodelling conditions for 500 beats at 1 Hz pacing, followed by 500 beats at 1.67 Hz (PCL = 
600 ms) pacing, and finally followed by 1 Hz pacing for 500 beats. The APD90 adaptation during the 
1.67 Hz pacing was fitted for slow AP adaptation rates. Bottom panels: CVr in 1D models under 
control (gray lines) and β-blockade (solid black lines) conditions. 
 
FIGURE 5 Re-entrant waves in 3D atria models. Row wise panels show results for each of the three 
models under control and β-block induced remodelling conditions. A: Representative frames from the 
3D simulations are shown in the first 3 columns, with arrows indicating approximate path of scroll 
waves to inferior vena cava (IVC) model boundary. B: Period of localised excitation. 
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Table 
Table 1. Summary of the multi-scale numerical results under β-block-induced remodelling and control 
conditions. 
Quantity CRN 
(β-blocker, 
Control) 
Grandi 
(β-blocker, 
Control) 
KT 
(β-blocker, 
Control) 
Text section 
Cell simulations 
APD90 (ms) (Expt. 
data 7, 12 :  
β-blocker: 238 ms; 
non-β-blocker: 
186) 
355.4, 302.8 433.0, 334.2 299.2, 238.1 2.1 
APD30 (ms) 139.8, 148 76.1, 66.2 30, 26.5 2.1 
dV/dtmax (mV/ms) 203.6, 206.7 101.2, 108.7 53.6, 55.54 2.1 
OS (mV) 37.6, 36.03 9.5, 28.5 38.7, 36.1 2.1 
RP (mV) -77.8, -81.2 -68.6, -73.4 -75.9, -77.2 2.1 
triangulation 
(mV/ms) 
4.6, 3.2 8.8, 6.1 5.9, 4.6 2.1 
S1-S2 APDr 
max. slope  
0.97, 1.2 0.88, 2.8 1.9, 1.2 2.2 
ERP (ms) 432, 347 850, 650 375, 318 2.2 
Alternans PCL 
range (ms) 
295-410, alternans 
suppressed 
Alternans not 
observed 
200-263, 
alternans 
suppressed 
2.2 
Slow time 
constant of APD 
adaptation (ms) 
258, 217 96, 111 257, 255 2.3 
1D simulations 
1D maximum 
pacing rate (Hz) 
2.8, 3.1 (9.6%) 2.2, 3 (26.6%) 4.4, 5.1 (13.7%) 2.4 
 19 
1D wavelength 
of propagation 
(mm), low PCL 
124, 105 55.6, 55.7 106.6, 83.3 2.4 
1D wavelength 
of propagation 
(mm), fast PCL 
(ms) 
35.4 (350), 36.1 
(317) 
21.4 (464), 22.9 
(329) 
15.3 (227), 12.6 
(195) 
2.4 
Temporal VW 
(ms) 
12.7, 10.1 24, 18.8 11.5, 15.8 2.4 
Tissue ERP (ms) 399.4, 370.5 (8%) 433.8, 362.7 
(19.6%) 
263.2, 215.0 
(10%) 
2.4 
3D re-entry simulations 
Re-entry LS (s) 0.4, > 5 0.5, > 5 > 5 s in both 
cases 
2.5 
Average re-entry 
period (ms) 
< 150, 360 < 250, 635 380, 290 2.5 
 
